AR

Adam Rosenberg

Director at Ambagon Therapeutics

Adam Rosenberg, JD, is a Venture Partner at RA Capital Management. Adam was most recently President, CEO, and member of the board of directors of Rodin Therapeutics until its acquisition by Alkermes in 2019. Adam has more than 20 years of industry experience in building healthcare and technology companies, including as CEO and co-founder of Link Medicine, a company focused on developing disease-modifying neurodegenerative therapies, and as CEO and co-founder of Teleos Therapeutics, an innovative neuroscience drug discovery platform company. Adam has led and advised companies in diverse areas such as digital health, materials, and diagnostics, and has served as a director on the boards of multiple venture-backed companies. Adam was also an advisor and investor in “A Late Quartet,” an entrepreneurial feature film centered on a cellist diagnosed with Parkinson’s disease, starring Philip Seymour Hoffman, Catherine Keener, and Christopher Walken. Adam received his JD from the University of Virginia School of Law and his BA from Whittier College.

Timeline

  • Director

    Current role